GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Adhera Therapeutics ATRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

—

FY2014FY2023

Net income

−$4.5m

FY2014FY2023

Free cash flow

−$714,193

FY2014FY2023

Shareholders' equity

—

FY2014FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue———$132,000$252,000$76,186——$680,000$500,000
Gross profit———$27,000−$157,000−$383,000−$451,000−$49,189$680,000$500,000
Research and development—————$240,982$907,493$108,858$801,000$686,000
Operating income−$1.3m−$1.6m−$674,000−$2.0m−$11.3m−$15.8m−$6.1m−$758,000−$4.0m−$3.5m
Net income−$4.5m$2.4m−$6.4m−$3.8m−$12.0m−$16.8m−$6.2m−$837,000$3.3m−$6.5m
Diluted earnings per share-1.040.74-0.37-0.34-1.10-2.09-0.59-0.0920.30-52.57

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets—$79,000$196,000$1,000$420,000$5.1m$6.2m$6.2m$7.6m$9.2m
Cash and short-term investments—$32,000$76,000$1,000$50,000$3.9m$106,378$105,347$710,000$1.8m
Total liabilities—$22.3m$25.3m$14.8m$10.3m$2.2m$5.7m$3.0m$7.3m$13.6m
Debt—$8.6m$6.7m$6.3m$5.3m—$1.9m$685,998—$1.6m
Shareholders' equity—−$22.2m−$25.1m−$14.8m−$9.9m$2.9m$448,243$3.2m$263,000−$4.4m
Shares outstanding4m3m17m11m11m8m11m9m0m0m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$714,193−$1.4m−$665,000−$588,000−$8.7m−$9.6m−$1.3m−$522,314−$2.2m−$4.8m
Capital spending—————−$74,364−$375,000−$74,000−$45,000—
Free cash flow−$714,193−$1.4m−$665,000−$588,000−$8.7m−$9.7m−$1.6m−$596,314−$2.2m−$4.8m
Dividends paid—−$620,000−$2.1m−$1.5m−$1.5m−$1.1m——−$690,000−$6.0m

Latest quarters

By quarter end

Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021
Operating income−$269,000−$296,000−$353,000−$361,000−$548,000−$449,000−$260,000−$203,000
Net income−$3.5m$271,000−$886,000−$335,000−$1.8m$99,000−$74,000−$1.7m
Diluted earnings per share-0.820.06-0.21-0.11-0.570.03-0.02-0.10
Total assets$44,074$82,000$104,000$79,000$256,000$976,000$170,000$196,000
Cash and short-term investments$32,388$58,000$69,000$32,000$133,000$849,000$40,000—
Debt$10.1m$10.6m$9.6m$8.6m$8.0m$7.3m$6.8m—
Shareholders' equity−$26.3m−$22.8m−$23.1m−$22.2m−$21.8m−$20.0m−$25.5m−$25.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-14.4%-39.5%13.4%
Net income6.0%-23.2%11.1%

Valuation history

At each fiscal year end

FY2020FY2019FY2018FY2017FY2016FY2013FY2012FY2010FY2004
Price to earnings———-0.0-0.0-0.1-0.0——
Price to sales0.10.00.1——0.10.10.00.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-92%-12%129%-61%63%253%-61%-85%8%-31%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 6 Oct 2022
  • 10-to-1 reverse split · 3 Aug 2017
  • 10-to-1 reverse split · 23 Dec 2011
  • 4-to-1 reverse split · 22 Jul 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.